New Delhi: world lung day (WLD) – September 25 reminds us to think about lung health and the increasing incidence of lung diseases; and calls to address untimely treatment access for these diseases.
According to Global Burden of Disease data and other research studies, out of over 90 million patients with lung diseases, only 10 million have access to the right management of lung care in India. It appears that 90 per cent of lung patients are deprived of lung care, which highlights the huge gap in access to treatment.
To fill this gap, Alkem Laboratories Ltd.World Lung Day 2021, launched PulmocareA division to raise awareness, diagnosis and management for lung diseases such as asthma, COPDThrough a wide range of products for Allergy, Advanced Lung Disease and Lung Care Lung Infection aims to bring about a paradigm shift in access to lung treatment in India through early diagnosis, better patient access and prompt health promotion .
Reasons for the high lung disease burden have been identified as low use of diagnostic tools such as spirometry, inadequate patient awareness of the disease, and delays in patient health care. This results in massive health loss resulting in death and/or disability-adjusted life-years (DALYs).
Sandeep Singh, Managing Director, alkemo Laboratories Ltd. said. “Taking into account of bridging the large gap in lung care access for the large population in India, we have taken a giant leap to address the massive lung disease burden in the country by launching a comprehensive lung care division – Pulmocare. With Alchemlaunch of the Pulmocare Division, we will spread awareness about the disease among patients and encourage them to use the right medicine.”
Adding further, Sandeep emphasized, “Alkem, over the years, has always been at the forefront of providing high quality patient care through its innovation and patient-centric initiatives. We are the most preferred partners for doctors in transition. Management, nutraceuticals, gastric-care and pediatric care.”
Founded in 1973 and headquartered in Mumbai, Alkem (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) is a leading Indian pharmaceutical company with global operations engaged in the development, manufacture and sale of pharmaceuticals. happened. and nutraceutical products. The company manufactures branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and international markets.
With a portfolio of over 800 brands in India, Alkem is the fifth largest pharmaceutical company in India in terms of domestic sales (Source: IQVIA March 2021). The company also has a presence in more than 40 international markets, including United States of america Its major focus being the market.
According to Global Burden of Disease data and other research studies, out of over 90 million patients with lung diseases, only 10 million have access to the right management of lung care in India. It appears that 90 per cent of lung patients are deprived of lung care, which highlights the huge gap in access to treatment.
To fill this gap, Alkem Laboratories Ltd.World Lung Day 2021, launched PulmocareA division to raise awareness, diagnosis and management for lung diseases such as asthma, COPDThrough a wide range of products for Allergy, Advanced Lung Disease and Lung Care Lung Infection aims to bring about a paradigm shift in access to lung treatment in India through early diagnosis, better patient access and prompt health promotion .
Reasons for the high lung disease burden have been identified as low use of diagnostic tools such as spirometry, inadequate patient awareness of the disease, and delays in patient health care. This results in massive health loss resulting in death and/or disability-adjusted life-years (DALYs).
Sandeep Singh, Managing Director, alkemo Laboratories Ltd. said. “Taking into account of bridging the large gap in lung care access for the large population in India, we have taken a giant leap to address the massive lung disease burden in the country by launching a comprehensive lung care division – Pulmocare. With Alchemlaunch of the Pulmocare Division, we will spread awareness about the disease among patients and encourage them to use the right medicine.”
Adding further, Sandeep emphasized, “Alkem, over the years, has always been at the forefront of providing high quality patient care through its innovation and patient-centric initiatives. We are the most preferred partners for doctors in transition. Management, nutraceuticals, gastric-care and pediatric care.”
Founded in 1973 and headquartered in Mumbai, Alkem (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) is a leading Indian pharmaceutical company with global operations engaged in the development, manufacture and sale of pharmaceuticals. happened. and nutraceutical products. The company manufactures branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and international markets.
With a portfolio of over 800 brands in India, Alkem is the fifth largest pharmaceutical company in India in terms of domestic sales (Source: IQVIA March 2021). The company also has a presence in more than 40 international markets, including United States of america Its major focus being the market.
.